Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.69 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6405251 | 1.00 | MAPT (0.69) | MAPTRXFP1LTB4RHDAC3HDAC4 | |
| SCHEMBL9663875 | 1.00 | MAPT (0.69) | MAPTRXFP1LTB4RHDAC3HDAC4 | |
| SCHEMBL10276969 | 1.00 | MAPT (0.69) | MAPTRXFP1LTB4RHDAC3HDAC4 | |
| SCHEMBL11204036 | 1.00 | MAPT (0.69) | MAPTRXFP1LTB4RHDAC3HDAC4 | |
| SCHEMBL951697 | 1.00 | MAPT (0.69) | MAPTRXFP1LTB4RHDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL10952981 | 0.98 | LTB4R (0.67) | MAPTRXFP1LTB4RHDAC3HDAC4 | |
| SCHEMBL2418582 | 0.98 | LTB4R (0.66) | MAPTRXFP1LTB4RHDAC3HDAC4 | |
| SCHEMBL1570239 | 0.92 | HDAC3 (0.67) | MAPTRXFP1LTB4RHDAC3HDAC4 | |
| SCHEMBL27670746 | 0.90 | HDAC3 (0.64) | MAPTRXFP1LTB4RHDAC3HDAC4 | |
| SCHEMBL9671779 | 0.90 | MAPT (0.83) | MAPTRXFP1LTB4RHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110300791-A | Quantum dot dispersion, self-luminous photosensitive resin composition, color filter, and image display device | 东友精细化工有限公司 | 2019-10-01 | — | — | CN | disclosed |
| CN-101448836-B | Pyridopyrimidinone derivatives | HOFFMAN-LA ROCHE LTD. (CH) | 2011-12-14 | — | — | CN | disclosed |
| EP-2029601-B1 | PYRIDOPYRIMIDINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-7572801-B2 | Pyridopyrimidinone derivatives which are HM74A agonists | HOFFMANN-LA ROCHE INC. (US) | 2009-08-11 | — | — | US | disclosed |
| CN-101448836-A | Pyridopyrimidinone derivatives | HOFFMANN LA ROCHE (CH) | 2009-06-03 | — | — | CN | disclosed |
| EP-2029601-A1 | PYRIDOPYRIMIDINONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| US-20070275987-A1 | Novel pyridopyprimidinone derivatives which are HM74A agonists | HOFFMAN-LA ROCHE INC | 2007-11-29 | — | — | US | disclosed |
| WO-2007134986-A1 | PYRIDOPYRIMIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-5998433-A | THERAPY FOR HYPERLIPIDEMIA; ATHEROSCLEROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| CN-1160403-A | Substd. heterobicyclic alkyl amines and their use as squalene oxide cyclase inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-09-24 | — | — | CN | disclosed |
| EP-0785939-A1 | SUBSTITUTED HETEROBICYCLIC ALKYL AMINES AND THEIR USE AS SQUALENE OXIDE CYCLASE INHIBITORS | Takeda Chemical Industries, Ltd. (JP) | 1997-07-30 | — | — | EP | disclosed |
| WO-1996011201-A1 | SUBSTITUTED HETEROBICYCLIC ALKYL AMINES AND THEIR USE AS SQUALENE OXIDE CYCLASE INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-04-18 | — | — | WO | disclosed |
| US-4536346-A | TREATMENT OF ATHEROSCLEROSIS | AMERICAN CYANAMID COMPANY (US) | 1985-08-20 | — | — | US | disclosed |
| EP-0124791-A1 | Aralkanamidophenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1984-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275987-A1 | Novel pyridopyprimidinone derivatives which are HM74A agonists | GPR119, HCAR1, GPR84 | MAPT 4450/4885RXFP1 171/4885LTB4R 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.